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Previewsactivate wild-type EGFR on other tumor
cells (Inda et al., 2010). One could imagine
that loss of IkBa in EGFRwild-type glioma
could increase NF-kB activity and IL-6
levels, which can further activate EGFR.
In the tumors analyzed by Bredel et al.
(2010), monoallelic, but not biallelic, loss
of NFKBIA was observed. There are
several potential interpretations of this
result, again requiring further analysis.
Loss of one copy of NFKBIA appears to
be advantageous to the tumor, possibly
for the reasons described above and/or
for other reasons. However, it seems to
be disadvantageous to lose both copies,
as it was not observed in any of the data-
sets Bredel et al. utilized. Perhaps this
speaks to the need to retain some degree
of control and inducibility over the NF-kB
pathway (Figure 1). Another possibility is
that IkBa has roles besides its most
well-studied function as an NF-kB inhib-
itor and this is critical for oncogenesis or
survival of cells of this particular lineage.
Deletions of NFKBIA in glioblastomas
reported by Bredel et al. (2010) add tothe documented mutations in the NF-kB
pathway. Given the percentage of tumors
with NFKBIA deletion and the impact on
patient survival, this event seems to be
significantly involved in glioblastoma
development, potentially providing new
targets for therapy. Future work requires
further analysis of the downstream
effects, particularly on the NF-kB
pathway. Comparison ofNFKBIA-deleted
and EGFR-amplified tumors will be impor-
tant in determining whether these two
alterations lead to a common phenotype
or if they characterize two distinct subsets
of glioblastoma. Potentially, the implica-
tion is that NF-kB signaling could be
centrally involved in all gliomas, although
the mutations responsible may vary
between subsets.REFERENCES
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A recent article in the New England Journal of Medicine by O’Shaughnessy et al. provides evidence that
a treatment strategy aimed at inducing DNA damage with chemotherapy while simultaneously disabling
repair using a PARP inhibitor might offer hope for patients with a treatment-refractory form of breast cancer.Many key genes inactivated in human
cancer are involved in DNA damage and
repair responses. Thus, specific DNA
repair defects in tumor cells might be tar-
geted selectively for therapeutic benefit
in otherwise resistant malignancies. The
emerging use of poly(ADP-ribose) poly-
merase (PARP) inhibitors in certain DNA
repair-deficient cancers promises to fulfill
this paradigm. Joyce O’Shaughnessy
and colleagues recently demonstrated
that treating patients with advanced‘‘triple-negative’’ breast cancers using
the PARP inhibitor iniparib in combination
with DNA-damaging chemotherapy in-
creased tumor responses and prolonged
patient survival compared with chemo-
therapy treatment alone (O’Shaughnessy
et al., 2011). Like many important clinical
advances however, this study leaves
many unresolved questions, and address-
ing these will be critical to realizing the
substantial promise of PARP inhibitors in
cancer therapy.PARPs catalyze the NAD+-dependent
addition of poly(ADP-ribose) units to tar-
get proteins and regulate diverse cellular
processes (Krishnakumar and Kraus,
2010). Most cellular PARP activity is
attributable to PARP1, a ubiquitous and
abundant nuclear protein that localizes
to sites of DNA damage, leading to the
recruitment of DNA repair proteins. Both
PARP1 and PARP2 have been linked to
base-excision repair, and Parp1 null
mice exhibit defective single-strandFebruary 15, 2011 ª2011 Elsevier Inc. 165
Figure 1. PARP Inhibitor Treatment of BRCA1/2-Associated and Sporadic Cancers
Normal cells have intact base excision repair and homologous recombination that are mediated by PARP and BRCA1/2-dependent pathways, respectively. In
germlineBRCA1 orBRCA2mutation carriers, the capacity for HR is often lost during tumorigenesis due to the inactivation of the remaining wild-type allele. PARP
inhibitor treatment disables the repair of spontaneous DNA damage in these tumor cells, leading to their death. Sporadic tumors including triple-negative breast
cancer may have defects in BRCA1/2 expression and/or function. Treatment combining a PARP inhibitor with DNA-damaging chemotherapy may be an effective
strategy for some of these tumors. (Illustration courtesy of Zachary Nash.)
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Previewsbreak repair (Krishnakumar and Kraus,
2010). Nevertheless, PARP-deficient
cells are able to carry out error-free DNA
repair through homologous recombina-
tion (HR), a process mediated by large
protein complexes whose components
include proteins encoded by the breast
cancer susceptibility genes BRCA1 or
BRCA2. This led to the hypothesis that
following PARP inhibition, normal cells
would effectively repair spontaneous
DNA damage—most commonly single-
strand breaks resulting in stalled replica-
tion forks—through HR. In contrast,
BRCA1/2-deficient cells would be unable
to carry out repair, ultimately leading to
persistent double-strand breaks and cell
death. In vitro studies confirmed the pre-
dicted ‘‘synthetic lethality’’ between
PARP and BRCA1/2 pathways (Bryant
et al., 2005; Farmer et al., 2005). Thus,
an effective clinical strategy and a poten-
tially large therapeutic window were sug-
gested for the use of PARP inhibitors as
single agents in patients with BRCA1/2-
associated cancers, whose tumors have
lost both copies of BRCA1/2 and are HR
deficient but whose normal cells retain166 Cancer Cell 19, February 15, 2011 ª2011one functional copy and are HR compe-
tent (Figure 1).
These observations prompted the
development of several PARP inhibitors
that are now being tested in clinical
trials. Olaparib (AZD2281) and veliparib
(ABT888) are competitive inhibitors that
mimic nicotinamide and compete for the
catalytic domain of PARP1 and PARP2
(He et al., 2010). In keeping with its pre-
dicted mechanism, olaparib has been
tested as a single agent in patients with
advanced cancers, and significant tumor
regression has been observed only in
those with BRCA1/2-associated tumors
(Fong et al., 2009; Tutt et al., 2010). Ini-
parib (BSI-201), the compound used in
the O’Shaugnessy study, is, in contrast,
a noncompetitive inhibitor of PARP1 that
disrupts the interaction between PARP1
and DNA.
Notwithstanding the elegant develop-
ment and validation of PARP inhibitors
for BRCA1/2-associated tumors, these
cancers are relatively uncommon. A
more complicated question regards the
rational use of PARP inhibitors in non-
BRCA1/2-associated tumors. A case inElsevier Inc.point are triple-negative breast cancers,
which lack expression of estrogen re-
ceptor (ER) and progesterone receptor
(PR) as well as Her-2 amplification, and
represent about 15% of all breast cancers
(Foulkes et al., 2010). While 80% of
BRCA1-associated breast cancers are
triple-negative, the vast majority of triple-
negative tumors arise sporadically in
noncarriers, yet these two subsets share
many distinct features (Foulkes et al.,
2010). In the context of PARP inhibition,
this begs the question whether BRCA1
and/or HR are functionally defective in
both sporadic and BRCA1-associated
triple-negative tumors. Many studies
have reported that sporadic triple-nega-
tive tumors express low levels of
BRCA1, owing to distinct mechanisms
(Moskwa et al., 2011), and display various
DNA damage response and repair
defects. However, it has been challenging
to demonstrate a profound defect in HR in
sporadic triple-negative tumors. Further-
more, patients with such tumors have
not demonstrated responses in small
clinical studies using olaparib (Fong
et al., 2009) or veliparib (Isakoff et al.,
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Previews2010). These experiences have prompted
the testing of PARP inhibition in combina-
tion with DNA-damaging chemothera-
peutics, which in theory could kill tumor
cells by overwhelming the cellular DNA
repair apparatus even in the absence of
an intrinsic HR defect (Figure 1). An unre-
solved question, however, was how
selective this approach would be for
tumor versus normal cells.
In light of these concerns, the findings
of O’Shaughnessy et al. (2011) are all the
more remarkable. In this study, patients
with advanced triple-negative breast
cancer who were unselected for BRCA1/
2 mutation status and who had received
only one or two lines of previous chemo-
therapy were randomized to receive com-
bination chemotherapy (gemcitabine, a
nucleoside analog, and carboplatin, a
DNA alkylating and crosslinking agent),
either alone or together with iniparib. The
addition of iniparib increased the tumor
response rate from 32% to 52% of
patients (O’Shaughnessy et al., 2011).
Historically, even in the face of an im-
provement in response rates, it is un-
common to observe prolonged patient
survival in such trials. This is because
patients receive other therapies following
completion of the trial, and, as in this trial,
patients are allowed to ‘‘cross-over’’ and
receive the study drug once their tumor
begins to progress. Strikingly, however,
the addition of iniparib in this trial in-
creased the overall survival of these
patients from 7.7 to 12.3 months. A larger
(Phase III) clinical study that has already
completed patient enrollment seeks to
validate these findings.
How do we interpret the results of this
trial in the context of the synthetic lethality
between PARP and BRCA1/2-HR path-
ways? Although the number of BRCA1/2
carriers enrolled in this trial was not re-
ported, based on population frequencies
it can be assumed that the majority ofpatients were not, and therefore at least
some of the clinical benefit occurred in
noncarriers. Especially notable in this trial
was the absence of significant combined
toxicity with the addition of iniparib to
chemotherapy. Inparticular, therewas little
or no additive bone marrow toxicity (a
correlate ofDNAdamage),which contrasts
withmarkedbonemarrowtoxicity reported
when veliparib and chemotherapy were
combined (Isakoff et al., 2010). As noted
above, iniparib has a distinct mechanism
of action. Further, in cell-based assays, in-
iparib exhibits potency in the micromolar
range compared with the low nanomolar
range displayed by other PARP inhibitors.
Indeed, no maximally tolerated dose has
been established for this agent (He et al.,
2010). Thus, while iniparib represents an
exciting compound from the clinical
perspective, its precise mechanism of
action remains to be defined.
Going forward, it is clear that PARP
inhibitors will be an important component
of therapy for cancers arising in BRCA1/2
carriers. Their application will likely extend
to early-stage disease, with the hope that
they might provide additional clinical
benefits.PARP inhibition is alsoaplausible
cancer preventative strategy in this set-
ting. In theory, limited exposure to such
an inhibitor might have little effect on
normal cells but could eliminate nascent
cancer cells that have undergone loss-of-
heterozygosity forBRCA1/2.Thesepoten-
tial benefits will have to be weighed
against potential toxicities, given the
established role of PARP in DNA repair,
metabolism, and stem cell function (Krish-
nakumar and Kraus, 2010). In sporadic
cancers, future clinical studies with addi-
tional PARP inhibitors are likely to further
clarify the potential role of these agents,
most likely in combination with DNA-
damaging therapeutics. Parallel preclin-
ical and translational studies to identify
the most effective chemotherapy partnersCancer Cell 19,and themost relevant in vivo targets of the
different PARP inhibitors will be essential
to the rational design of future trials. Most
exciting is the possibility that future work
will uncover additional synthetic lethal
relationships between PARP-dependent
pathways and tumor-specific defects
present in sporadic cancers (He et al.,
2010). If successful, such studies may
fulfill the promise of a rational synthetic
lethal approach for many common
cancers.REFERENCES
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